ð ç« æ«éèš
- C. trachomatis â obligate intracellular, EB/RB lifecycle, energy parasite
- 15 serotypes: A-C trachoma, D-K genital/neonatal, L1-L3 LGV
- Treatment 2021 CDC: doxycycline 100 bid à 7d (preferred); azithro 1 g à 1 (pregnancy)
- LGV: doxy à 21d; MSM proctitis (L2b)
- PID: ceftriaxone + doxy + metro; infertility consequence
- Fitz-Hugh-Curtis: perihepatitis (chlamydia or gonorrhea)
- Reactive arthritis: HLA-B27, post-STD
- Neonatal: conjunctivitis (5-12d) + pneumonia (2-12 wk); erythromycin 14d
- Trachoma: A-C serotypes, leading infectious blindness; SAFE strategy, WHO elimination 2030
- Co-screen HIV + syphilis + gonorrhea + HBV; re-screen 3 mo
- Doxy-PEP 2024: 200 mg PO within 72 hr (MSM), reduces 70%